Effect of cilastatin on cyclosporine-induced acute nephrotoxicity in kidney transplant recipients

Transplantation

Volumn 64, Issue 1, 1997, Pages 164-166

  Carmellini, Mario ^a,b   Frosini, Fabiana ^a   Filipponi, Franco ^a   Boggi, Ugo ^a   Mosca, Franco ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CILASTATIN; CILASTATIN PLUS IMIPENEM; CYCLOSPORIN A; METHYLPREDNISOLONE; OKT 3; PREDNISONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; CADAVER; CILASTATIN; CREATININE; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEASE INHIBITORS;

EID: 0030787401     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707150-00029     Document Type: Article

References (13)

1. The Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986; 314: 1219.
2. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28: 767.
3. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30: 964.
4. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephrotoxicity. N Engl J Med 1984; 311: 699.
5. Calne RY, Rolles K, White DJG, et al. Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 1979; 2: 1033.
6. Taube DH, Neild GH, Williams DG, et al. Differentiation between allograft rejection and cyclosporine nephrotoxicity in renal-transplant recipients. Lancet 1985; 2: 171.
7. Sido B, Hammer C, Mraz W, Krombach F. Nephroprotective effect of imipenem/cilastatin in reducing cyclosporine toxicity. Transplant Proc 1987; 19: 1755.
8. Hammer C, Thies JC, Mraz W, Mihatasch M. Reduction of cyclosporine nephrotoxicity by imipenem/cilastatin after kidney transplantation in rats. Transplant Proc 1989; 21: 931.
9. Klintmalm GBC, Iwatsuki S, Starzl TE. Nephrotoxicity of cyclosporine A in liver and kidney transplant patients. Lancet 1981; 1: 970.
10. Parrott NR, Forsythe JLR, Matthews JNS, et al. Late perfusion: a simple remedy for renal allograft primary nonfunction. Transplantation 1990; 49: 413.
11. Mihatsch MJ, Steiner K, Abejwickrama KM, et al. Risk factors for the development of chronic cyclosporine-nephrotoxicity. Transplant Proc 1988; 20: 812.
12. Markewitz A, Hammer C, Pfeiffer M, et al. Reduction of cyclosporine-induced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation 1994; 57: 865.
13. Baghaie A, Bayat M, Abobo C, et al. The effect of imipenem/ cilastatin on acute cyclosporine nephrotoxicity in heart/lung transplant patients. Crit Care Med 1995; 23: A241.